Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Car-t symbols : Nvs save search
Global CAR-T Therapy Pipeline Analysis Market Report 2023: Increasing Financial Support Provided by Different Organizations to Promote Development and Consumption Drives Growth
Published: 2023-04-06 (Crawled : 22:00) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
report pipeline global car-t financial therapy growth market
CAR-T Cell Therapy Market Size to Reach USD 9.62 Million in 2030| Emergen Research
Published: 2023-01-09 (Crawled : 16:00) - prnewswire.com
ALPMF | News | $9.5 43.47% 1.2K
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: 0.0%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 3.12%
H: 0.0%
C: -2.55%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 0.58%
H: 0.44%
C: -0.31%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.76%
H: 0.26%
C: -3.27%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.29%
H: 0.27%
C: -3.89%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.16%
H: 0.05%
C: -2.89%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: 1.42%
H: 0.64%
C: -2.27%
research car-t therapy market
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
Published: 2022-05-27 (Crawled : 23:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
| Email alert
Add to watchlist
kymriah fda novartis car-t therapy
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
kymriah novartis europe car-t positive therapy chmp t-cell
Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.17%
H: 0.5%
C: -0.43%
novartis car-t platform charging
New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio
Published: 2021-11-04 (Crawled : 15:15) - globenewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: -0.89%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.06%
H: 0.28%
C: 0.18%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 2.41%
H: 0.0%
C: 0.0%
ema car-t platform
Global CAR-T Therapy Pipeline Report 2021: Market is Expected to Stabilize and Reach $6,100 Million in 2030
Published: 2021-10-29 (Crawled : 12:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.84%
H: 0.18%
C: 0.18%
therapy car-t
Global CAR-T Cell Therapy Markets to 2026: Rising Clinical Trials and Development of New and Effective Therapy Options
Published: 2021-09-28 (Crawled : 16:00) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -0.12%
H: 1.77%
C: -0.99%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.16%
H: 0.04%
C: -0.51%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.5%
C: -0.18%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.09%
H: 0.93%
C: -0.26%
SGMO | News | $0.4911 -5.72% -6.07% 1.2M
|
Health Technology
|
| O: -1.12%
H: 0.52%
C: -2.17%
AUTL | $4.23 -5.58% -5.91% 2.7M
|
Health Technology
|
| O: -2.67%
H: 1.27%
C: -5.48%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.38%
H: 1.16%
C: -0.01%
clinical trials therapy car-t trials trial t-cell
Alberta sites join network of certified centres to deliver CAR-T therapy, Kymriah (tisagenlecleucel)
Published: 2021-04-28 (Crawled : 14:00) - biospace.com/
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.37%
H: 0.7%
C: 0.58%
therapy car-t liver
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.